(News Bulletin 247) – Sensorion on Monday unveiled preliminary data presented as “promising” as part of its Phase 2a study devoted to the prevention of residual hearing loss after cochlear implantation.

In five out of five patients, the presence of SENS-401, its lead drug candidate, was confirmed in the perilymph seven days after the start of the study, a level ‘compatible’ with therapeutic efficacy.

These results confirm that SENS-401 crosses the labyrinthine barrier and can have an effect on the preservation of residual hearing, explains the biotech in a press release.

According to the company, the presence of SENS-401 in the cochlea of ​​100% of patients having undergone a cochlear implantation procedure reinforces the potential profile of this small molecule.

Sensorion plans to share additional data from this trial in combination with cochlear implants at a webinar on July 5th.

Study patients, who started treatment seven days prior to implantation, should continue to receive SENS-401 for 42 days.

The study is also supposed to assess a number of secondary endpoints in the implanted ear, including the change in hearing threshold at several frequencies between the start and end of the study.

Following these announcements, Sensorion shares were stable on the Paris Stock Exchange on Monday, having erased all their gains after jumping nearly 13% in the early morning. The title still jumped 19% over the past month.

Copyright (c) 2023 News Bulletin 247. All rights reserved.